Literature DB >> 29657085

Structural Determinants for Small-Molecule Activation of Skeletal Muscle AMPK α2β2γ1 by the Glucose Importagog SC4.

Kevin R W Ngoei1, Christopher G Langendorf2, Naomi X Y Ling3, Ashfaqul Hoque3, Swapna Varghese4, Michelle A Camerino5, Scott R Walker5, Ylva E Bozikis5, Toby A Dite3, Ashley J Ovens6, William J Smiles3, Roxane Jacobs7, He Huang8, Michael W Parker9, John W Scott10, Mark H Rider7, Richard C Foitzik11, Bruce E Kemp10, Jonathan B Baell12, Jonathan S Oakhill13.   

Abstract

The AMP-activated protein kinase (AMPK) αβγ heterotrimer regulates cellular energy homeostasis with tissue-specific isoform distribution. Small-molecule activation of skeletal muscle α2β2 AMPK complexes may prove a valuable treatment strategy for type 2 diabetes and insulin resistance. Herein, we report the small-molecule SC4 is a potent, direct AMPK activator that preferentially activates α2 complexes and stimulates skeletal muscle glucose uptake. In parallel with the term secretagog, we propose "importagog" to define a substance that induces or augments cellular uptake of another substance. Three-dimensional structures of the glucose importagog SC4 bound to activated α2β2γ1 and α2β1γ1 complexes reveal binding determinants, in particular a key interaction between the SC4 imidazopyridine 4'-nitrogen and β2-Asp111, which provide a design paradigm for β2-AMPK therapeutics. The α2β2γ1/SC4 structure reveals an interaction between a β2 N-terminal α helix and the α2 autoinhibitory domain. Our results provide a structure-function guide to accelerate development of potent, but importantly tissue-specific, β2-AMPK therapeutics.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AMP-activated protein kinase; X-ray crystallography; diabetes; drug development; glucose disposal; importagog; metabolism; secretagog

Mesh:

Substances:

Year:  2018        PMID: 29657085     DOI: 10.1016/j.chembiol.2018.03.008

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  12 in total

1.  Conformational heterogeneity of the allosteric drug and metabolite (ADaM) site in AMP-activated protein kinase (AMPK).

Authors:  Xin Gu; Michael D Bridges; Yan Yan; Parker W de Waal; X Edward Zhou; Kelly M Suino-Powell; H Eric Xu; Wayne L Hubbell; Karsten Melcher
Journal:  J Biol Chem       Date:  2018-09-11       Impact factor: 5.157

2.  Structures of AMP-activated protein kinase bound to novel pharmacological activators in phosphorylated, non-phosphorylated, and nucleotide-free states.

Authors:  Yan Yan; X Edward Zhou; Scott J Novick; Simon J Shaw; Yingwu Li; Joseph S Brunzelle; Yasumichi Hitoshi; Patrick R Griffin; H Eric Xu; Karsten Melcher
Journal:  J Biol Chem       Date:  2018-11-26       Impact factor: 5.157

Review 3.  AMPK: restoring metabolic homeostasis over space and time.

Authors:  Elijah Trefts; Reuben J Shaw
Journal:  Mol Cell       Date:  2021-09-16       Impact factor: 19.328

4.  Structure-function analysis of the AMPK activator SC4 and identification of a potent pan AMPK activator.

Authors:  Ashley J Ovens; Yi Sing Gee; Naomi X Y Ling; Dingyi Yu; Justin P Hardee; Jin D Chung; Kevin R W Ngoei; Nicholas J Waters; Nolan J Hoffman; John W Scott; Kim Loh; Katrin Spengler; Regine Heller; Michael W Parker; Gordon S Lynch; Fei Huang; Sandra Galic; Bruce E Kemp; Jonathan B Baell; Jonathan S Oakhill; Christopher G Langendorf
Journal:  Biochem J       Date:  2022-06-17       Impact factor: 3.766

5.  Proposed Allosteric Inhibitors Bind to the ATP Site of CK2α.

Authors:  Paul Brear; Darby Ball; Katherine Stott; Sheena D'Arcy; Marko Hyvönen
Journal:  J Med Chem       Date:  2020-10-29       Impact factor: 7.446

Review 6.  AMP-Activated Protein Kinase and Host Defense against Infection.

Authors:  Prashanta Silwal; Jin Kyung Kim; Jae-Min Yuk; Eun-Kyeong Jo
Journal:  Int J Mol Sci       Date:  2018-11-06       Impact factor: 5.923

Review 7.  Post-Translational Modifications of the Energy Guardian AMP-Activated Protein Kinase.

Authors:  Ashley J Ovens; John W Scott; Christopher G Langendorf; Bruce E Kemp; Jonathan S Oakhill; William J Smiles
Journal:  Int J Mol Sci       Date:  2021-01-27       Impact factor: 5.923

8.  The myokine meteorin-like (metrnl) improves glucose tolerance in both skeletal muscle cells and mice by targeting AMPKα2.

Authors:  Jung Ok Lee; Won Seok Byun; Min Ju Kang; Jeong Ah Han; Jiyoung Moon; Min-Jeong Shin; Ho Jun Lee; Ji Hyung Chung; Jin-Seok Lee; Chang-Gue Son; Kwon-Ho Song; Tae Woo Kim; Eun-Soo Lee; Hong Min Kim; Choon Hee Chung; Kevin R W Ngoei; Naomi X Y Ling; Jonathan S Oakhill; Sandra Galic; Lisa Murray-Segal; Bruce E Kemp; Kyoung Min Kim; Soo Lim; Hyeon Soo Kim
Journal:  FEBS J       Date:  2020-04-19       Impact factor: 5.542

9.  Synthetic energy sensor AMPfret deciphers adenylate-dependent AMPK activation mechanism.

Authors:  Martin Pelosse; Cécile Cottet-Rousselle; Cécile M Bidan; Aurélie Dupont; Kapil Gupta; Imre Berger; Uwe Schlattner
Journal:  Nat Commun       Date:  2019-03-04       Impact factor: 14.919

10.  Direct small molecule ADaM-site AMPK activators reveal an AMPKγ3-independent mechanism for blood glucose lowering.

Authors:  Nicolas O Jørgensen; Rasmus Kjøbsted; Magnus R Larsen; Jesper B Birk; Nicoline R Andersen; Bina Albuquerque; Peter Schjerling; Russell Miller; David Carling; Christian K Pehmøller; Jørgen F P Wojtaszewski
Journal:  Mol Metab       Date:  2021-05-23       Impact factor: 7.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.